Saturday 17 October 2026
Export ANIX’s income statement to Excel — free account
ANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00. In the quarter to July 2026, EPS fell 14.3% and free cash flow fell 17.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.67
0.11
−3.96%
Follow ANIX
ANIXA BIOSCIENCES INC (ANIX) P/E ratio
ANIXA BIOSCIENCES INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Apr 2023 | 0.0× | — |
| Oct 2021 | 0.0× | — |
| Jan 2021 | 0.0× | — |
| Apr 2019 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| ICCC ImmuCell Corporation compare | 126× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)